Featured CME topic: dementia. Medication update.
Slagle
M A
MA
D000544:Alzheimer Disease / Q000188:drug therapy*; D002219:Carbamates / Q000009:adverse effects / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D000075202:Contraindications; D000077265:Donepezil; D004347:Drug Interactions; D004877:Ergoloid Mesylates / Q000009:adverse effects / Q000627:therapeutic use; D005702:Galantamine / Q000009:adverse effects / Q000627:therapeutic use; D020441:Ginkgo biloba / Q000627:therapeutic use; D006801:Humans; D007189:Indans / Q000009:adverse effects / Q000627:therapeutic use; D018697:Nootropic Agents / Q000009:adverse effects / Q000627:therapeutic use; D048448:Phenylcarbamates; D008517:Phytotherapy; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use; D010946:Plants, Medicinal; D000068836:Rivastigmine
D002219:Carbamates; D002800:Cholinesterase Inhibitors; D007189:Indans; D018697:Nootropic Agents; D048448:Phenylcarbamates; D010880:Piperidines; D005702:Galantamine; D004877:Ergoloid Mesylates; D000077265:Donepezil; D000068836:Rivastigmine